Qiagen, a medical diagnostics company, is planning to launch a portable coronavirus test that can process up to 30 patient samples per hour and deliver results within 15 minutes. The new test would ...
Qiagen shares were higher after the medical-diagnostics company launched an antigen test to detect coronavirus infections within two to 15 minutes. Shares of Qiagen (QGEN) rose after the medical ...
Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will ...
QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...
/PRNewswire-FirstCall/ - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health ...
Qiagen's careHPV for use in areas with limited healthcare infrastructure--Courtesy of PATH Dutch molecular diagnostics conglomerate Qiagen ($QGEN) launched its new ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback